<img src="https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7?size=2" nborder="0" align="left" hspace="5" vspace="5" title="22157.jpg" alt="Company Logo"/>Opportunities include equitable access, provider training, resilient supply chains, integrated postpartum and adolescent care, and privacy-first digital education and follow-up.<div style="float:right;padding:0 0 15px 20px;margin:15px 0 20px 20px;width:300px">
 Long-acting Contraception Market
 <figure>
 <img src="https://ml.globenewswire.com/Resource/Download/26208077-b97a-46b9-9bcc-387c0d10e4bd" title="Long-acting Contraception Market" alt="Long-acting Contraception Market" />
 <figcaption>Long-acting Contraception Market</figcaption>
 </figure>
</div>Dublin, Aug. 18, 2026 <a href="https://www.globenewswire.com" target="_blank">(GLOBE NEWSWIRE)</a> -- The <a href="https://www.researchandmarkets.com/report/long-acting-contraception?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=3h49xg&amp;utm_campaign=2327902+-+Long-Acting+Contraception+Market+Report%3a+Evaluating+Hormonal+vs.+Non-Hormonal+IUDs%2c+Subdermal+Implants%2c+Injectables%2c+and+Strategies+of+Bayer%2c+Merck%2c+Pfizer%2c+and+CooperCompanies&amp;utm_exec=clshmsai" rel="nofollow" target="_blank" title="Long-acting Contraception Market - Global Forecast 2026-2032">"Long-acting Contraception Market - Global Forecast 2026-2032"</a> has been added to ResearchAndMarkets.com's offering. <img alt="" height="400" src="//www.researchandmarkets.com/content-images/2525/2525754/1/long-acting-contraception-market.png" width="600" /> The global long-acting contraception market research report provides strategic analysis of a sector projected to reach USD 7.35 billion in 2026 and grow at a CAGR of 8.29% to USD 11.87 billion by 2032. It examines intrauterine devices, contraceptive implants, and injectable contraceptives, alongside the policy, technology, healthcare delivery, and demographic factors shaping demand. Market Overview Long-acting contraception provides highly effective pregnancy prevention with minimal user action after initiation. Its adoption is supported by expanding family planning services, greater awareness of contraceptive choice, integration with postpartum and post-abortion care, and increased attention to adolescent and young adult reproductive health. Affordability, provider training, counseling quality, cultural acceptance, supply continuity, and public policy remain decisive market factors. The report's assessment of these dynamics supports strategic planning, risk evaluation, and identification of underserved populations and service gaps. Transformative Market Shifts The market is moving from product-focused availability toward rights-based, patient-centered contraceptive ecosystems. Intrauterine devices, implants, and injectables are increasingly incorporated into primary care, maternal health, adolescent health, and community services. Key developments include: . Expanded reimbursement and publicly funded family planning programs . Task-sharing among physicians, nurses, midwives, and trained community health workers . Greater emphasis on informed consent, side-effect management, and continuation support . Stronger procurement, inventory visibility, and last-mile distribution . Increased use of telehealth, digital scheduling, electronic records, and mobile education Artificial Intelligence and Digital Health Artificial intelligence is influencing clinical decision support, demand forecasting, supply-chain optimization, pharmacovigilance, and patient engagement. Predictive analytics can identify potential stockouts and improve the allocation of products and trained providers. Multilingual digital tools can also support education, reminders, and general side-effect guidance. Adoption depends on validated clinical content, privacy safeguards, cybersecurity, equitable data representation, and protection against biased or coercive recommendations. These insights allow healthcare and technology leaders to evaluate digital investments while managing regulatory, ethical, and reputational risks. Regional and Economic Group Insights Asia-Pacific benefits from large reproductive-age populations, government family planning programs, and expanding digital health infrastructure, although rural access and counseling quality vary. Europe has strong regulation and public health infrastructure, with country-specific reimbursement and method preferences. North America offers established clinical guidance and provider networks, but affordability and policy differences continue to create disparities. Latin America combines growing awareness with public procurement and health-system challenges. Africa remains central to donor-supported and public-sector expansion, while provider shortages, misinformation, and stock reliability affect uptake. The Middle East is seeing gradual growth through urban healthcare and maternal health services. NATO and G7 markets generally feature advanced clinical standards and pharmacovigilance systems. BRICS countries combine large public programs and manufacturing capacity with uneven access. The EU benefits from regulatory coordination, while ASEAN growth reflects primary care and maternal health expansion. GCC markets are supported by private healthcare investment and digital service adoption. Selected Country Insights China's market reflects established intrauterine device use and changing demographic policies. The United States is shaped by insurance, Medicaid, Title X services, and state-level rules. India is expanding injectables and postpartum intrauterine contraception through public programs. The United Kingdom, Germany, France, Italy, and Spain benefit from structured healthcare systems, although reimbursement and service capacity differ. Australia, Canada, Japan, South Korea, Russia, Brazil, and Mexico present distinct opportunities based on regulatory history, public coverage, provider practices, cultural attitudes, and integration with maternal and adolescent health. Country-level comparisons inform market entry choices, partnership priorities, and localized access strategies. Actionable Priorities for Industry Leaders . Invest in provider training for insertion, removal, counseling, and method switching. . Strengthen demand planning, diversified sourcing, and last-mile supply visibility. . Build privacy-preserving digital education and follow-up services. . Partner with public agencies, primary care networks, and community organizations. . Expand real-world evidence and pharmacovigilance focused on safety, satisfaction, continuation, and discontinuation. Key Takeaways from This Report . The market is forecast to reach USD 11.87 billion by 2032. . Patient-centered service delivery, reliable supply, and informed choice are critical growth drivers. . AI and digital health offer operational advantages when supported by ethical governance. . Regional policy, financing, provider capacity, and cultural differences require localized strategies. . Sustainable competitive advantage depends on equitable access, trusted partnerships, and measurable care quality. Key Attributes: <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;"><tr><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-left: solid black 1pt ; ">Report Attribute</td><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; ">Details</td></tr><tr><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-left: solid black 1pt ; ">No. of Pages</td><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; ">185</td></tr><tr><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-left: solid black 1pt ; ">Forecast Period</td><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; ">2026 - 2032</td></tr><tr><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-left: solid black 1pt ; ">Estimated Market Value (USD) in 2026</td><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; ">$7.35 Billion</td></tr><tr><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-left: solid black 1pt ; ">Forecasted Market Value (USD) by 2032</td><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; ">$11.87 Billion</td></tr><tr><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-left: solid black 1pt ; ">Compound Annual Growth Rate</td><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; ">8.2%</td></tr><tr><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; ">Regions Covered</td><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; ">Global</td></tr></table> Key Topics Covered: 1. Preface 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Segmentation &amp; Coverage 1.4. Years Considered for the Study 1.5. Currency Considered for the Study 1.6. Language Considered for the Study 1.7. Key Stakeholders 2. Research Methodology 2.1. Introduction 2.2. Research Design 2.2.1. Primary Research 2.2.2. Secondary Research 2.3. Research Framework 2.3.1. Qualitative Analysis 2.3.2. Quantitative Analysis 2.4. Market Size Estimation 2.4.1. Top-Down Approach 2.4.2. Bottom-Up Approach 2.5. Data Triangulation 2.6. Research Outcomes 2.7. Research Assumptions 2.8. Research Limitations 3. Executive Summary 3.1. Introduction 3.2. CXO Perspective 3.3. Market Size &amp; Growth Trends 3.4. New Revenue Opportunities 3.5. Next-Generation Business Models 3.6. Industry Roadmap 4. Market Overview 4.1. Introduction 4.2. Industry Ecosystem &amp; Value Chain Analysis 4.2.1. Supply-Side Analysis 4.2.2. Demand-Side Analysis 4.2.3. Stakeholder Analysis 4.3. Market Dynamics 4.3.1. Key Drivers 4.3.2. Key Restraints 4.3.3. Key Opportunities 4.3.4. Key Challenges 4.4. Porter's Five Forces Analysis 4.5. PESTLE Analysis 4.6. Market Outlook 4.6.1. Near-Term Market Outlook (0-2 Years) 4.6.2. Medium-Term Market Outlook (3-5 Years) 4.6.3. Long-Term Market Outlook (5-10 Years) 4.7. Go-to-Market Strategy 5. Market Insights 5.1. Consumer Insights &amp; End-User Perspective 5.2. Consumer Experience Benchmarking 5.3. Opportunity Mapping 5.4. Distribution Channel Analysis 5.5. Pricing Trend Analysis 5.6. Regulatory Compliance &amp; Standards Framework 5.7. ESG &amp; Sustainability Analysis 5.8. Disruption &amp; Risk Scenarios 5.9. Return on Investment &amp; Cost-Benefit Analysis 6. Cumulative Impact of Artificial Intelligence 2026 7. Long-acting Contraception Market, by Product Type 7.1. Introduction 7.2. Intrauterine Devices 7.3. Contraceptive Implants 7.4. Injectable Contraceptives 7.5. Vaginal Rings 8. Long-acting Contraception Market, by Hormone Type 8.1. Introduction 8.2. Hormonal Contraceptives 8.3. Non-Hormonal Contraceptives 9. Long-acting Contraception Market, by Duration of Effectiveness 9.1. Introduction 9.2. 3-Year Contraceptives 9.3. 5-Year Contraceptives 9.4. 10-Year Contraceptives 10. Long-acting Contraception Market, by Delivery Mode 10.1. Introduction 10.2. Intrauterine 10.3. Subdermal 10.4. Intramuscular 10.5. Vaginal 10.6. Transdermal 11. Long-acting Contraception Market, by End User 11.1. Introduction 11.2. Hospitals 11.3. Gynecology Clinics 11.4. Family Planning Clinics 11.5. Community Health Centers 11.6. Ambulatory Surgical Centers 11.7. Homecare Settings 12. Long-acting Contraception Market, by Distribution Channel 12.1. Introduction 12.2. Offline 12.3. Online 13. Long-acting Contraception Market, by Region 13.1. Asia-Pacific 13.2. Europe 13.3. North America 13.4. Latin America 13.5. Africa 13.6. Middle East 14. Long-acting Contraception Market, by Group 14.1. NATO 14.2. G7 14.3. BRICS 14.4. European Union 14.5. ASEAN 14.6. GCC 15. Long-acting Contraception Market, by Country 15.1. China 15.2. United States 15.3. Japan 15.4. India 15.5. Germany 15.6. United Kingdom 15.7. Australia 15.8. France 15.9. South Korea 15.10. Italy 15.11. Canada 15.12. Russia 15.13. Brazil 15.14. Mexico 15.15. Spain 16. Competitive Landscape 16.1. Market Share Analysis, 2025 16.2. FPNV Positioning Matrix, 2025 16.3. Market Concentration Analysis, 2025 16.3.1. Concentration Ratio (CR) 16.3.2. Herfindahl Hirschman Index (HHI) 16.4. Recent Developments &amp; Impact Analysis, 2025 16.5. Product Portfolio Analysis, 2025 16.6. Benchmarking Analysis, 2025 17. Company Profiles 17.1. Bayer AG 17.2. Besins Healthcare 17.3. Changzhou Medical Bioengineering Co., Ltd. 17.4. CTTQ Pharmaceutical Group Co., Ltd. 17.5. Cupid Limited 17.6. Eurogine S.L. 17.7. Fuji Latex Co., Ltd. 17.8. Guangzhou Tianhe Medical Technology Co., Ltd. 17.9. Innova Medical Oy 17.10. Laboratoire 7 MED 17.11. Mankind Pharma Limited 17.12. Merck KGaA 17.13. Mona Lisa N.V. 17.14. Ningbo Jiulong Medical Instruments Co., Ltd. 17.15. OCON Healthcare Ltd. 17.16. Organon &amp; Co. 17.17. Pregna International Limited 17.18. Reckitt Benckiser Group plc 17.19. Rusan Pharma Ltd. 17.20. Shanghai Dahua Pharmaceutical Co., Ltd. 17.21. Shenzhen JCR Medical Technology Ltd. 17.22. SMB Corporation of India 17.23. Teva Pharmaceutical Industries Ltd. 17.24. Theramex HQ UK Limited 17.25. TherapeuticsMD, Inc. 17.26. UMEDO Co., Ltd. 17.27. Viatris Inc. 17.28. Zhejiang Aimake Medical Technology Co., Ltd. For more information about this report visit <a href="https://www.researchandmarkets.com/report/long-acting-contraception?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=3h49xg&amp;utm_campaign=2327902+-+Long-Acting+Contraception+Market+Report%3a+Evaluating+Hormonal+vs.+Non-Hormonal+IUDs%2c+Subdermal+Implants%2c+Injectables%2c+and+Strategies+of+Bayer%2c+Merck%2c+Pfizer%2c+and+CooperCompanies&amp;utm_exec=clshmsai" rel="nofollow" target="_blank" title="">https://www.researchandmarkets.com/r/r7bomz</a> About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. 
 Attachment

<ul id="gnw_attachments_section-items">
 <li>
 <a target="_blank" href="https://ml.globenewswire.com/Resource/Download/26208077-b97a-46b9-9bcc-387c0d10e4bd" title="Long-acting Contraception Market" rel="nofollow">Long-acting Contraception Market</a>
 </li>
 </ul>
<pre>CONTACT: 
CONTACT: ResearchAndMarkets.com 
 Laura Wood,Senior Press Manager 
 press@researchandmarkets.com
 For E.S.T Office Hours Call 1-917-300-0470 
 For U.S./ CAN Toll Free Call 1-800-526-8630 
 For GMT Office Hours Call +353-1-416-8900 

</pre> <img alt="" src='https://ml.globenewswire.com/media/MzI3Y2M4OTctYTI4MC00NjU4LThkZjgtMzc3ZDRhNjMzZDMwLTEwMjY3MzctMjAyNi0wOC0xOC1lbg==/tiny/Research-and-Markets.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

Long-Acting Contraception Market Report: Evaluating Hormonal vs. Non-Hormonal IUDs, Subdermal Implants, Injectables, and Strategies of Bayer, Merck, Pfizer, and CooperCompanies

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn